The information presented in this manual will help laboratory technicians, scientists, extension officers, policymakers and private vaccine distributors to improve their understanding of the principles of effective storage and handling of vaccines.
It is well established that a primary component of East Coast Fever is parasite-driven proliferation of the cow’s lymphocytes. Unknown until now was the important role of the cow’s macrophages in driving an inflammatory response resulting in injury to blood vessels in the lung and respiratory failure.
Vish Nene reflects on the 2016 ECF consortium meeting north of London – the discussions, the people, the next steps.
Tremendous progress has been made over the last ten years on East Coast fever (ECF) research.
Peste des petits ruminants virus (PPRV) causes an economically important disease of sheep and goats, primarily in developing countries. It is becoming the object of intensive international control efforts. Current vaccines do not allow vaccinated and infected animals to be distinguished (no DIVA capability).
The Infection and Treatment Method (ITM) of vaccination against the apicomplexan parasite Theileria parva has been used since the early 1970s and is still the only commercially available vaccine to combat the fatal bovine disease, East Coast fever (ECF). The disease is tick-transmitted and results in annual economic losses of at least $300 million per year.
A sub-group of the members of the ECF Consortium held a two-day meeting in Oxford to discuss one of the Consortium objectives, “To induce T-cell mediated immunity by targeting the schizont stage of the parasite.”
To be held 22-26 May 2016 in Cape Town, an important component of this Keystone Symposia meeting will be to stimulate crosstalk between the human and veterinary vaccine communities by highlighting cross-cutting technical advances and new science and knowledge from laboratory and field research.
The International Livestock Research Institute (ILRI) is part of a collaborative project that will develop and assess the assays on FMD vaccine strains currently being produced in East Africa by the Kenya Veterinary Vaccines Production Institute (KEVEVAPI), with the intention of transferring the technologies for their future application.
LRI and GALVmed recently convened a workshop on the ‘distribution, delivery and improvement of the Infection and Treatment Method vaccine for East Coast fever (ECF)’.